HIV and Cardiovascular Disease: Lipids, Inflammation, and More — 2026 Update

Assessment of Needs

Cardiovascular risk management in people with HIV (PWH) is rapidly evolving, with growing debate around statin initiation in patients previously considered low risk. This webinar will highlight emerging, practice-changing insights, including the Predicting Risk of Cardiovascular Disease Events (PREVENT) risk score. Updated blood pressure guidance and shifting lipid management recommendations will be discussed to support integrated, HIV-specific cardiovascular prevention strategies.

Learning Objectives

On completion of this activity, learners will be able to:

• Describe the role of statins in PWH, including in those at low estimated cardiovascular risk
• Apply updated risk stratification tools, including the PREVENT score and emerging biomarkers such as lipoprotein(a)
• Incorporate current guideline recommendations for lipid and blood pressure management into the care of patients with HIV

Registration

Who Should Attend

This webinar is designed for clinical decision makers who are actively involved in HIV care and research, including physicians, physician assistants, nursing professionals, pharmacists, and other health care professionals.

Individual registration is required in order to receive CME credit or a certificate of participation.

Registration closes on Wednesday, June 3, 2026, 11:30 AM (PT).

For more information or questions, please contact the registration department at registration@iasusa.org or 415-544-9400.

Conflicts of Interest

In the interest of maintaining the independence of its continuing medical education (CME) activities, the International Antiviral Society–USA (IAS–USA) requires all persons with control of educational content (eg, faculty, Scientific Leadership Board, Governance Board, and program planner) to disclose any financial relationships with ineligible companies (previously defined as “commercial interests”) that they have had within the past 24 months. Any real or apparent conflicts of interest of those parties are resolved and mitigated prior to the CME activity being delivered. Individuals who refuse to disclose financial interests may not participate in IAS–USA CME activities. 

The Accreditation Council for Continuing Medical Education (ACCME) defines ineligible companies as “those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.”

IAS–USA will identify and resolve ahead of time any possible conflicts of interest that may influence CME activities with regard to exposition or conclusion. Information about financial relationships with ineligible companies for the presenter and planners/reviewers is below and in the slides prior to the presentation of educational content.

Presenter

Dr Hsue reported serving on the scientific advisory board of Marea Therapeutics and as consultant to Gilead Sciences, Inc, MSD, Pfizer, Inc, Genentech, Inc, and ViiV Healthcare; receiving research grant funding from Novartis AG, Abbott Laboratories, Excision BioTherapeutics, Inc, and Eli Lilly and Company; and receiving noncash provisions of study drugs from Novartis AG, Regeneron Pharmaceuticals, Inc, and Eli Lilly and Company. (Updated March 13, 2026)

Moderator

Dr Feinstein reported receiving consulting or advisor fees from Gilead Sciences, Inc. and Novo Nordisk. (Updated March 18, 2026)

Planner/Reviewer

Planner/Reviewer 1 reported no relevant financial relationships with ineligible companies. (Updated April 1, 2026)
Planner/Reviewer 2 reported no relevant financial relationships with ineligible companies. (Updated April 1, 2026)

COW Board

The financial relationships of the COW Board can be found here: https://www.iasusa.org/activities/cases-on-the-web/about-cows/cow-webinars-editorial-board/